The US Bankruptcy Court granted an order for the joint administration of the Chapter 11 bankruptcy cases of DMK Pharmaceuticals Corporation, and its affiliates on February 6, 2024. The affiliates include U.S. Compounding, Inc., Rhombus Pharmaceuticals Corporation, Biosyn, Inc. and Adamis Corporation. The cases would be jointly administered for administrative and procedural purposes.

DMK Pharmaceuticals Corporation, has been designated as the lead debtor.